NCT01995695View on ClinicalTrials.gov

Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

January 31, 2016

Conditions
Influenza A Virus, H7N9 Subtype
Interventions
BIOLOGICAL

Live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine

Participants will receive approximately 10\^7.0 focus forming units (FFU) of the live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine. The vaccine will be delivered by an Accuspray nasal spray device (0.25 mL per nostril for a total of 0.5 mL of vaccine).

BIOLOGICAL

Inactivated subvirion H7N9 influenza vaccine

Participants will receive 30 mcg of the inactivated subvirion H7N9 vaccine by intramuscular injection.

Trial Locations (1)

14642

University of Rochester Medical Center, Rochester

All Listed Sponsors
collaborator

University of Rochester

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT01995695 - Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults | Biotech Hunter | Biotech Hunter